TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05930873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive room
Description: The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: stimuli in a paper format
Description: The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces).
Study: NCT04928365

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 therapy
Study: NCT04778384

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
Study: NCT05215327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
Study: NCT05212532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOM613
Description: peptide nucleic acid (PNA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOM613
Description: peptide nucleic acid (PNA)
Study: NCT04994574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Description: From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.
Study: NCT06381635

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Manuka honey mixed with aloe vera gel
Description: a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey mixed with aloe vera gel
Description: a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
Study: NCT05493904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided PCI
Description: For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~1. By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane \[EEL\] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex\> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~2. By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex\> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
Study: NCT04083859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-Lung
Description: A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lung health video
Description: Web-based video about guideline recommended exercise for lung health
Study: NCT05911841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06233760

Intervention type: OTHER
Intervention: WHOQOL-BREF
Description: WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items

Intervention type: OTHER
Intervention: Routine assessment of patient index data 3 (RAPID-3)
Description: RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30

Intervention type: OTHER
Intervention: Big Five Inventory
Description: The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.

Intervention type: OTHER
Intervention: Family APGAR Questionnaire
Description: Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
Study: NCT05404360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainsWay Deep TMS HAC/H7-Coil
Description: The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BrainsWay Deep TMS Sham Coil
Description: The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment.
Study: NCT06400771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNP007
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNP007
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNP007
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNP007
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
Study: NCT06141460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRG001
Description: Administered via Subretinal injection. Dosage form: injection solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRG001
Description: Administered via Subretinal injection. Dosage form: injection solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRG001
Description: Administered via Subretinal injection. Dosage form: injection solution.
Study: NCT06695507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib for 6 months.
Study: NCT06695715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Program
Description: This mindfulness training program is based on the Mindfulness-Based Stress Reduction (MBSR) model developed by Jon Kabat-Zinn, incorporating elements of self-compassion and acceptance. What sets this program apart is its integration of both formal and informal practices. Participants engage in 45-minute guided sessions focused on breath awareness and the observation of thoughts, emotions, and physical sensations. Additionally, informal practices include brief daily moments of present-moment awareness. Participants will also receive 10 audio recordings for at-home practice, enhancing the program's accessibility and supporting consistency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback
Description: This HRV biofeedback training program is distinguished by its combination of advanced technology and a novel at-home methodology. Participants will engage in five weekly sessions, with four conducted at home using a heart rate sensor and the EliteHRV mobile app, which provides real-time feedback on heart rate variability. One session per week will take place in the lab, utilizing the Procomp Infiniti biofeedback system. The at-home approach is based on recent research (Schumann et al., 2021), offering participants a flexible yet structured method to practice biofeedback and improve heart rate variability over the six-week program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoception Training
Description: The interoception training program stands out by its focus on developing internal body awareness through structured guided sessions. Participants will engage in weekly 45-minute formal sessions at the university, where they will learn to focus on internal sensations like breath and muscle tension using specific techniques. Additionally, participants will receive 10 guided interoceptive exercises to practice at home, four times a week. This program not only focuses on the physical sensations but also integrates these practices into daily life, aiming to improve self-care and self-regulation over the six weeks, with personalized feedback provided.
Study: NCT06695143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusidic Acid
Description: Fusidic acid 2% cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream
Description: Cetomacrogol cream
Study: NCT06695962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone 10mg
Description: 30 mg per day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone 10mg
Description: 30 mg per day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 per day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 per day for 21 days

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: gastric emptying test
Description: gastric emptying test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: gastric emptying test
Description: gastric emptying test
Study: NCT06286852

Intervention type: BEHAVIORAL
Intervention: Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
Description: Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
Study: NCT06694324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin (Doxil)
Description: 30 mg/m2, d1, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, d1, IV
Study: NCT06694142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rosy app
Description: Participants will be provided a six-month membership subscription to the mobile application ROSY. ROSY will recommend pathways for addressing issues through 1) coaching by board certified coaches or 2) joining a completely anonymous community with other people where they can share experiences and get help as new members of the community to overcome sexual health challenges .Users will work towards their health goals each day using tools from medical and mental health experts . Tools used include 1) virtual workshops and 2) coaching sessions which will provide the opportunity to a) Have an authentic and relatable conversation with an expert b) Explore new pathways to better health experience c) Improve their relationship with themselves, partner, and healthcare providers d) Learn fun ways to improve their everyday wellness e) Access live events from anywhere.
Study: NCT06694636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular radiofrequency ablation and desympathetic nerve surgery
Description: endovascular radiofrequency ablation and desympathetic nerve surgery
Study: NCT06687850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: The canine was included in therapy sessions to determine the effect of the canine on prosocial behavior and emotional regulation in autistic children with varying verbality.
Study: NCT06630390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Administered consistent with labeling from the US Food and Drug Administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing to daridorexant
Study: NCT06690827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD123 CAR NK cells
Description: Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
Study: NCT06689774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Motivational Feedback
Description: Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Motivational Feedback
Description: Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.
Study: NCT06425705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
Study: NCT06012929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is an oral medication given once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is an oral medication given once per week
Study: NCT06322407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB)
Description: All SGB procedures will be performed by the same experienced physicians. Patients will be positioned in a supine position with the neck slightly hyperextended and receive a SGB procedure using the B-ultrasound visualization technique (Aurora A5 Ultrasound, Risco Tech Co., Ltd.). 1% lidocaine 5mL (Shanxi Jinxin Shuanghe Pharm Co., Ltd.) will be injected below the prevertebral fascia on the surface of longus colli muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standardized drug treatment
Description: Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standardized drug treatment
Description: Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
Study: NCT06441019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab
Description: The patient will receive combined treatment with HAIC, TQB2868, and Ramucirumab. After enrollment, the patient will undergo routine hepatic artery angiography via femoral artery catheterization and placement of a hepatic artery catheter，they will then receive 150ml of 5% sodium bicarbonate + Oxaliplatin (85mg/m2) for 4-6 hours + Raltitrexed (2mg/m2) for 2-4 hours . This will be done every 3-4 weeks for at least 2 cycles. Systemic treatment will be administered every 21 days, with TQB2868 injection given on the first day of each cycle (1-7 days after HAIC). The fixed dose of TQB2868 will be 300mg, and Ramucirumab will be given at a dose of 500mg (initial intravenous infusion for 60 minutes, followed by 30 minutes if tolerated).
Study: NCT05012072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Mastery Lifestyle Intervention
Description: Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST